The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer.
Otto Metzger-Filho
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Ian E. Krop
No relevant relationships to disclose
W. Jerry Younger
No relevant relationships to disclose
Elizabeth S Lawler
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Nancy U. Lin
No relevant relationships to disclose